Automated Staining Aids Real-Time Tumor Calls - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Automated Staining Aids Real-Time Tumor Calls

Automated frozen-section staining helped classify selected ambiguous tumors and margins in a single-center validation study.

  • By

  • Andrea Surnit

  • May 11, 2026

  • 3 min

Share

Clinical Scorecard: Automated Staining Aids Real-Time Tumor Calls

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationPatients undergoing intraoperative frozen-section assessment for various tumor types.
Care Setting

Key Highlights

  • FFRA-IHC improved classification in 68% of previously unclassifiable tumors, including carcinomas and lymphomas.

Guideline-Based Recommendations

Diagnosis

  • Utilize FFRA-IHC for rapid classification of ambiguous tumors.
  • Conduct larger studies to validate the effectiveness of FFRA-IHC.

Management

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        FFRA-IHC can redirect management from surgical to hematologic evaluation by providing rapid classification.

        Clinical Best Practices

        • Communicate initial frozen-section diagnosis before initiating FFRA-IHC.
        • Consider the limitations of the antibody panel when interpreting results, especially in ambiguous cases.

        Related Resources & Content

        Original Source(s)

        Automated Staining Aids Real-Time Tumor Calls

        • by Andrea Surnit

        • May 11, 2026

        Related Content

        Sex Differences Seen in Immune Cells

        Single-cell analysis identified sex-biased immune-cell composition, gene expression, and genetic regulation in unstimulated blood immune cells

        Consensus Guidance May Improve Sinonasal Mass Outcomes

        Multidisciplinary recommendations emphasize biopsy technique, imaging, and pathology review in patients with suspected sinonasal malignancy.

        FDA Expands Test for Gastric and Esophageal Cancers

        According to Agilent Technologies, the expanded indication covers esophageal and gastric tumor types and applies to patients being considered for nivolumab or nivolumab and hyaluronidase-nvhy.